Want to see AMRN full AI Analyst Report?
AMRN Stock Chart & Stats
$14.15
$0.09(0.66%)
At close: 4:00 PM EDT
$14.15
$0.09(0.66%)
Day’s Range― - ―
52-Week Range$11.25 - $17.31
Previous CloseN/A
Volume31.49K
Average Volume (3M)65.90K
Market Cap
$255.30M
Enterprise Value-$40.12M
Total Cash (Recent Filing)$323.38M
Total Debt (Recent Filing)$7.61M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 03, 2027EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding21,073,238
10 Day Avg. Volume70,630
30 Day Avg. Volume65,904
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.63
Price to Sales (P/S)1.36
P/FCF Ratio42.95
Enterprise Value/Market Cap-0.16
Enterprise Value/Revenue-0.23
Enterprise Value/Gross Profit-0.56
Enterprise Value/Ebitda2.24
Forecast
1Y Price Target
$13.00Price Target Upside-8.13% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.6
Revenue Forecast (FY)$177.44M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe total revenues included a $25M upfront payment from the Recordati deal, contributing to the overall revenue growth.
Strategic PartnershipsThe Recordati partnership in Europe helps reshape Amarin's business model by transferring commercialization to a seasoned local partner with established cardiovascular infrastructure and expertise.
Bears Say
Competition ChallengesThe longer-term outlook for the US Vascepa business remains conservative given growing pressure from generic competitors.
Market CompetitionInvestors may remain cautious about the commercial business as the US VASCEPA franchise continues to face significant pressure from at least eight generic competitors.
Amarin News
AMRN FAQ
What was Amarin Corporation Plc’s price range in the past 12 months?
Amarin Corporation Plc lowest stock price was $11.25 and its highest was $17.31 in the past 12 months.
What is Amarin Corporation Plc’s market cap?
Amarin Corporation Plc’s market cap is $255.30M.
When is Amarin Corporation Plc’s upcoming earnings report date?
Amarin Corporation Plc’s upcoming earnings report date is Mar 03, 2027 which is in 122 days.
How were Amarin Corporation Plc’s earnings last quarter?
Amarin Corporation Plc released its earnings results on Oct 28, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.097 by $0.097.
Is Amarin Corporation Plc overvalued?
According to Wall Street analysts Amarin Corporation Plc’s price is currently Overvalued.
Does Amarin Corporation Plc pay dividends?
Amarin Corporation Plc does not currently pay dividends.
What is Amarin Corporation Plc’s EPS estimate?
Amarin Corporation Plc’s EPS estimate is -0.08.
How many shares outstanding does Amarin Corporation Plc have?
Amarin Corporation Plc has 21,073,238 shares outstanding.
What happened to Amarin Corporation Plc’s price movement after its last earnings report?
Amarin Corporation Plc reported an EPS of $0 in its last earnings report, beating expectations of -$0.097. Following the earnings report the stock price went up 6.653%.
Which hedge fund is a major shareholder of Amarin Corporation Plc?
Currently, no hedge funds are holding shares in AMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amarin Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$13.00 (-8.13% Downside)
$13.00 (-8.13% Downside)
Blogger Sentiment
Bullish
AMRN Sentiment 71%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Increased
By 12.2K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.15%
12-Months-Change
Fundamentals
Return on Equity
-4.26%
Trailing 12-Months
Asset Growth
-3.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Amarin Corporation Plc
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
AMRN Company Deck
AMRN Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive, supported by the first profitable quarter in two years, four consecutive quarters of positive operating cash flow, a stronger debt-free balance sheet, lower expenses, improving supply economics, strong international in-market demand growth, maintained U.S. market leadership, and encouraging overall survival data from EMT2. These positives were tempered by lower total and U.S. revenue, continued U.S. pricing pressure, lower European product revenue, variability in partner ordering, uncertainty around 2027 exclusivity, and EMT2's failure to meet its primary progression-free survival endpoint.View all AMRN earnings summariesAMRN Stock 12 Month Forecast
Average Price Target
$13.00
▼(-8.13% Downside)
Technical Analysis
Ownership Overview
0.74% Insiders
1.81% Mutual Funds
1.37% Other Institutional Investors
95.95% Public Companies and
Individual Investors